Farnesyl transferase inhibiting 1,8-annelated quinolinone...

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 471/06 (2006.01) A61K 31/47 (2006.01) C07D 455/04 (2006.01) C07D 498/06 (2006.01)

Patent

CA 2283587

This invention concerns compounds of formula (I), the pharmaceutically acceptable acid additions salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond; X is oxygen or sulfur; -A- is a bivalent radical of formula; R1 and R2 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, trihalomethyl, trihalomethoxy, C2-6alkenyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, C1-6alkyloxycarbonyl, aminoC1- 6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar, Ar-C1-6alkyl, Ar-oxy, Ar-C1-6alkyloxy; or when on adjacent positions R1 and R2 taken together may form a bivalent radical; R3 and R4 each independently are hydrogen, halo, cyano, C1-6alkyl, C1-6alkyloxy, Ar- oxy, C1-6alkylthio, di(C1-6alkyl)amino, trihalomethyl, trihalomethoxy; or when on adjacent positions R3 and R4 taken together may form a bivalent radical; R5 is an imidazolyl substituted with hydrogen or C1-6alkyl; R6 hydrogen, hydroxy, halo cyano, optionally substituted C1-6alkyl, C1-6alkyloxycarbonyl or Ar; or a radical of formula -O-R7, -S-R8, -N-R8R9; and Ar is optionally substituted phenyl; having farnesyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.

L'invention concerne des composés de formule (I), leurs sels d'addition acides pharmaceutiquement acceptables et leurs formes stéréo-isomères, où la ligne en pointillé représente une liaison facultative; X désigne oxygène ou soufre; -A- est un radical bivalent de formule; R<1> et R<2> sont chacun indépendamment hydrogène, hydroxy, halo, cyano, alkyle C1-6, trihalométhyle, trihalométhoxy, alcényle C2-6, alkyloxy C1-6, hydroxyalkyloxy C1-6, alkyloxyC1-6alkyloxy C1-6, alkyloxycarbonyle C1-6, aminoalkyloxy C1-6, mono ou di(alkyle C1-6)amino alkyloxy C1-6, Ar, Ar-alkyle C1-6, Ar-oxy, Ar-alkyloxy C1-6; ou R1-R2, lorsqu'ils sont adjacents et pris ensemble, peuvent former un radical bivalent; R3 et R4 désignent chacun indépendamment hydrogène, halo, cyano, alkyle C1-6, alkyloxy C1-6, Ar-oxy, alkylthio C1-6, di(C1-6alkyl)amino, trihalométhyle, trihalométhoxy; ou R<3> et R<4>, lorsqu'ils sont adjacents et pris ensemble, peuvent former un radical bivalent; R<5> est un imidazolyle substitué par un hydrogène ou alkyle C1-6; R<6> désigne hydrogène, hydroxy, halo, cyano, éventuellement alkyle C1-6 substitué, alkyloxycarbonyle C1-6 ou Ar; ou un radical de la formule -O-R<7>, -S-R<8>, -N-R<8>R<9>; et Ar désigne éventuellement phényle substitué. Lesdits composés ont une activité inhibant la transférase farnésyle. L'invention concerne aussi leur préparation, les compositions les contenant et leur utilisation en tant que médicament.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Farnesyl transferase inhibiting 1,8-annelated quinolinone... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Farnesyl transferase inhibiting 1,8-annelated quinolinone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Farnesyl transferase inhibiting 1,8-annelated quinolinone... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1966171

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.